AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The transcription factor CCAAT/enhancer binding protein alpha, or C/EBPalpha, encoded by the CEBPA gene, is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and Cebpa knockout mice exhibit an early block in maturation. Dominant-negative mutations of CEBPA have been found in some patients with acute myeloid leukemia (AML), but not in AML with the t(8;21) translocation which gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) encoding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eight-fold lower CEBPA RNA levels and undetectable C/EBPalpha protein levels compared with other subgroups of AML patients. Conditional expression of RUNX1-CBF2T1 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBPalpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expression of C/EBPalpha in AML1-ETO-positive Kasumi-1 cells results in neutrophilic differentiation. We suggest that restoring C/EBPalpha expression will have therapeutic implications in RUNX1-CBF2T1-positive leukemias.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and abolishes C/EBP 𝛂 expression. 54”
From RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. (2003) · cites this paper as [54]
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“The U937T cell line in which U937 cells were stably transfected with the tetracycline transactivator (tTA) under the control of a tetracycline responsive elemen”
BackgroundEstablishment and characterization of a human histiocytic lymphoma cell line (U‐937)
Sundström, C., & Nilsson, K. (1976) · International Journal of Cancer · doi:10.1002/ijc.2910170504 · Cited by 2,407
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Luciferase reporter gene vectors for analysis of promoters and enhancers.
Nordeen, S. K. (1988) · PubMed · Cited by 994
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910
Self-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901 · cited 1×
“a the abnormalities were one del (9)(q22;q34); one t(6;9); one t(10;21)(p11;q22); one 8;one 14; and one complex aberrant karyotype.”
BackgroundSelf-citationMiyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872
Cited by
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
van Galen, P., Hovestadt, V., Wadsworth II, M. H., Hughes, T. K., Griffin, G. K., Battaglia, S., Verga, J. A., Stephansky, J., Pastika, T. J., Lombardi Story, J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.031 · Cited by 1,164
“This is consistent with previously described repression of the myeloid differentiation factor CEBPA by the RUNX1-RUNX1T1 fusion gene (Pabst et al., 2001) and shows an association between expression states and genetics.”
Stems Cells and the Pathways to Aging and Cancer
Rossi, D. J., Jamieson, C. H. M., & Weissman, I. L. (2008) · Cell · doi:10.1016/j.cell.2008.01.036 · Cited by 895
“…in primitive progenitors contribute to cancer pathogenesis comes from an analysis of AML patients harboring t8;21 translocations generating the AML-1-ETO oncogene, the expression of which leads to decreased expression of the critical granulocytic differentiation factor, CEBP/a (Pabst et al., 2001).”
BackgroundDisruption of differentiation in human cancer: AML shows the way
Tenen, D. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc989 · Cited by 612
Self-citationTranscription factors in myeloid development: balancing differentiation with transformation
Rosenbauer, F., & Tenen, D. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2024 · Cited by 606
Self-citationWeisberg, E., Boulton, C., Kelly, L. M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D. G., & Griffin, J. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00069-7 · Cited by 599
Transcriptional regulation of erythropoiesis: an affair involving multiple partners
Cantor, A. B., & Orkin, S. H. (2002) · Oncogene · doi:10.1038/sj.onc.1205326 · Cited by 594
“…the work of Tenen and colleagues who have shown that the fusion protein AML1-ETO, the product of a chromosomal translocation found in blast cells of patients with a subtype of acute myelogenous leukemia, downregulates the essential Oncogene myeloid transcription factor C/EBPa (Pabst et al., 2001).”
BackgroundInfluentialG ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Self-citationZhang, P., Iwasaki-Arai, J., Iwasaki, H., Fenyus, M. L., Dayaram, T., Owens, B. M., Shigematsu, H., Levantini, E., Huettner, C. S., Lekstrom-Himes, J. A., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.11.006 · Cited by 504
Self-citationPreudhomme, C., Sagot, C., Boissel, N., Cayuela, J.-M., Tigaud, I., de Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0990 · Cited by 501
“(range) 45 (15-64) 45 (22-63) 45 (15-64) .”
Role of RUNX1 in hematological malignancies
Sood, R., Kamikubo, Y., & Liu, P. (2017) · Blood · doi:10.1182/blood-2016-10-687830 · Cited by 494
Cancer epigenetics: Moving forward
Nebbioso, A., Tambaro, F. P., Dell’Aversana, C., & Altucci, L. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007362 · Cited by 480
Fröhling, S., Schlenk, R. F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.060 · Cited by 458
C/EBPβ is required for 'emergency' granulopoiesis
Hirai, H., Zhang, P., Dayaram, T., Hetherington, C. J., Mizuno, S.-I., Imanishi, J., Akashi, K., & Tenen, D. G. (2006) · Nature Immunology · doi:10.1038/ni1354 · Cited by 425
Self-citationNerlov, C. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.004 · Cited by 402
Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the AML1/ETO Oncoprotein
Fazi, F., Racanicchi, S., Zardo, G., Starnes, L. M., Mancini, M., Travaglini, L., Diverio, D., Ammatuna, E., Cimino, G., Lo-Coco, F., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.09.020 · Cited by 382
Differentiation therapy of leukemia: 3 decades of development.
Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Mutation of CEBPA in Familial Acute Myeloid Leukemia
Smith, M. L., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041331 · Cited by 328
Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia
Mullican, S. E., Zhang, S., Konopleva, M., Ruvolo, V., Andreeff, M., Milbrandt, J., & Conneely, O. M. (2007) · Nature Medicine · doi:10.1038/nm1579 · Cited by 324
BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2
Perrotti, D., Cesi, V., Trotta, R., Guerzoni, C., Santilli, G., Campbell, K., Iervolino, A., Condorelli, F., Gambacorti-Passerini, C., Caligiuri, M. A., et al. (2002) · Nature Genetics · doi:10.1038/ng791 · Cited by 313
Mizuki, M., Schwäble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Böhmer, F. D., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1677 · Cited by 298
The 8;21 translocation in leukemogenesis
Peterson, L. F., & Zhang, D.-E. (2004) · Oncogene · doi:10.1038/sj.onc.1207727 · Cited by 302
“In U937 cells, however, the block of differentiation is accompanied by a decreased C/ EBPa expression (Burel et al., 2001; Pabst et al., 2001).”
BackgroundSelf-citationMüller-Tidow, C., Steffen, B., Cauvet, T., Tickenbrock, L., Ji, P., Diederichs, S., Sargin, B., Köhler, G., Stelljes, M., Puccetti, E., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2890-2904.2004 · Cited by 303
Kalev-Zylinska, M. L., Horsfield, J. A., Flores, M. V. C., Postlethwait, J. H., Vitas, M. R., Baas, A. M., Crosier, P. S., & Crosier, K. E. (2002) · Development · doi:10.1242/dev.129.8.2015 · Cited by 289
Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors
Johnson, P. F. (2005) · Journal of Cell Science · doi:10.1242/jcs.02459 · Cited by 288
“Experiments showing that reinstating C/EBPα expression in AML cells suppresses their proliferation in vitro and tumorigenicity in vivo support these conclusions (Truong et al., 2003).”
BackgroundInfluentialC/EBPα mutations in acute myeloid leukaemias
Nerlov, C. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1363 · Cited by 280
Wang, Y.-Y., Zhou, G.-B., Yin, T., Chen, B., Shi, J.-Y., Liang, W.-X., Jin, X.-L., You, J.-H., Yang, G., Shen, Z.-X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408831102 · Cited by 276
Schoch, C., Kohlmann, A., Schnittger, S., Brors, B., Dugas, M., Mergenthaler, S., Kern, W., Hiddemann, W., Eils, R., & Haferlach, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142103599 · Cited by 274
Self-citationChoudhary, C., Schwäble, J., Brandts, C., Tickenbrock, L., Sargin, B., Kindler, T., Fischer, T., Berdel, W. E., Müller-Tidow, C., & Serve, H. (2005) · Blood · doi:10.1182/blood-2004-07-2942 · Cited by 263
Alcalay, M., Meani, N., Gelmetti, V., Fantozzi, A., Fagioli, M., Orleth, A., Riganelli, D., Sebastiani, C., Cappelli, E., Casciari, C., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17595 · Cited by 249
Vangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245
Self-citationHeterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243
Self-citationThe Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation
Wang, L., Gural, A., Sun, X.-J., Zhao, X., Perna, F., Huang, G., Hatlen, M. A., Vu, L., Liu, F., Xu, H., et al. (2011) · Science · doi:10.1126/science.1201662 · Cited by 242
Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia
Keeshan, K., He, Y., Wouters, B. J., Shestova, O., Xu, L., Sai, H., Rodriguez, C. G., Maillard, I., Tobias, J. W., Valk, P., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.012 · Cited by 238
“Decreased C/EBPap42 levels are observed in diverse molecular subtypes of human AML (Helbling et al., 2004, 2005; Pabst et al., 2001a; Perrotti et al., 2002; Westendorf et al., 1998) and are sometimes associated with point mutations in C/EBPa (Pabst et al., 2001b).”
BackgroundThe AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice
Schessl, C., Rawat, V. P. S., Cusan, M., Deshpande, A., Kohl, T. M., Rosten, P. M., Spiekermann, K., Humphries, R. K., Schnittger, S., Kern, W., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24225 · Cited by 237
Self-citationvan Waalwijk van Doorn-Khosrovani, S. B., Erpelinck, C., Meijer, J., van Oosterhoud, S., van Putten, W. L. J., Valk, P. J. M., Berna Beverloo, H., Tenen, D. G., Löwenberg, B., & Delwel, R. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200216 · Cited by 235
Self-citationPreclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
Ranganathan, P., Yu, X., Na, C., Santhanam, R., Shacham, S., Kauffman, M., Walker, A., Klisovic, R., Blum, W., Caligiuri, M., et al. (2012) · Blood · doi:10.1182/blood-2012-04-423160 · Cited by 220
Akasaka, T., Balasas, T., Russell, L. J., Sugimoto, K.-J., Majid, A., Walewska, R., Karran, E. L., Brown, D. G., Cain, K., Harder, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-041012 · Cited by 215
Self-citationLin, L.-I., Chen, C.-Y., Lin, D.-T., Tsay, W., Tang, J.-L., Yeh, Y.-C., Shen, H.-L., Su, F.-H., Yao, M., Huang, S.-Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1816 · Cited by 214
“Interestingly, all patients with t(8;21), a chromosome translocation associated with down regulation of C/EBPa expression and function (29), showed CD15 expression on the leukemic cells, as shown in our previous study (17) and in this study (data not shown).”
ResultZhu, S., Yoon, K., Sterneck, E., Johnson, P. F., & Smart, R. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012437299 · Cited by 200
Wouters, B. J., Jordà, M. A., Keeshan, K., Louwers, I., Erpelinck-Verschueren, C. A. J., Tielemans, D., Langerak, A. W., He, Y., Yashiro-Ohtani, Y., Zhang, P., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073486 · Cited by 199
Self-citationBlock of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
Radomska, H. S., Bassères, D. S., Zheng, R., Zhang, P., Dayaram, T., Yamamoto, Y., Sternberg, D. W., Lokker, N., Giese, N. A., Bohlander, S. K., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052242 · Cited by 199
Self-citationCEBPA point mutations in hematological malignancies
Leroy, H., Roumier, C., Huyghe, P., Biggio, V, Fenaux, P., & Preudhomme, C. (2005) · Leukemia · doi:10.1038/sj.leu.2403614 · Cited by 190
AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia
Zhou, F., Liu, Y., Rohde, C., Pauli, C., Gerloff, D., Köhn, M., Misiak, D., Bäumer, N., Cui, C., Göllner, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3563 · Cited by 187
Ptasinska, A., Assi, S. A., Mannari, D., James, S. R., Williamson, D., Dunne, J., Hoogenkamp, M., Wu, M., Care, M., McNeill, H., et al. (2012) · Leukemia · doi:10.1038/leu.2012.49 · Cited by 184
Self-citationHeidenreich, O., Krauter, J., Riehle, H., Hadwiger, P., John, M., Heil, G., Vornlocher, H.-P., & Nordheim, A. (2003) · Blood · doi:10.1182/blood-2002-05-1589 · Cited by 175
de Guzman, C. G., Warren, A. J., Zhang, Z., Gartland, L., Erickson, P., Drabkin, H., Hiebert, S. W., & Klug, C. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5506-5517.2002 · Cited by 171
Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia
Gery, S., Gombart, A. F., Yi, W. S., Koeffler, C., Hofmann, W.-K., & Koeffler, H. P. (2005) · Blood · doi:10.1182/blood-2005-01-0358 · Cited by 168
Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation
Avellino, R., & Delwel, R. (2017) · Blood · doi:10.1182/blood-2016-09-687822 · Cited by 167
“The onco-protein RUNX1-RUNX1T1 has been for long associated with negative regulation of CEBPA expression in AML [110-113], but the mechanism underlying this interesting finding is poorly understood.”
BackgroundPabst, T., Eyholzer, M., Fos, J., & Mueller, B. U. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604977 · Cited by 163
“In AML patients, deregulation of CEBPA function is a common event comprising of genomic mutations (Pabst et al, 2001a; Frohling et al, 2004; Nerlov, 2004), transcriptional and posttranscriptional suppression (Pabst et al, 2001b; Helbling et al, 2004; Helbling et al, 2005), and inactivation by…”
BackgroundMethodSelf-citationReddy, V. A., Iwama, A., Iotzova, G., Schulz, M., Elsasser, A., Vangala, R. K., Tenen, D. G., Hiddemann, W., & Behre, G. (2002) · Blood · doi:10.1182/blood.v100.2.483 · Cited by 152
Self-citationHOX expression patterns identify a common signature for favorable AML
Andreeff, M., Ruvolo, V, Gadgil, S., Zeng, C., Coombes, K., Chen, W., Kornblau, S., Barón, A. E., & Drabkin, H. A. (2008) · Leukemia · doi:10.1038/leu.2008.198 · Cited by 149
Phosphorylation of C/EBPα Inhibits Granulopoiesis
Ross, S. E., Radomska, H. S., Wu, B., Zhang, P., Winnay, J. N., Bajnok, L., Wright, W. S., Schaufele, F., Tenen, D. G., & MacDougald, O. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.675-686.2004 · Cited by 146
Self-citationChell, V., Balmanno, K., Little, A. S., Wilson, M. I., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.319 · Cited by 156
Schwieger, M., Löhler, J., Friel, J., Scheller, M., Horak, I., & Stocking, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020824 · Cited by 143
“Significantly, granulocytic sarcomas are observed at a relatively high incidence in t(8;21) AML (54, 55), and can be the first manifestation of AML (56, 57).”
BackgroundResultInfluentialDichotomy of AML1-ETO Functions: Growth Arrest versus Block of Differentiation
Burel, S. A., Harakawa, N., Zhou, L., Pabst, T., Tenen, D. G., & Zhang, D.-E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5577-5590.2001 · Cited by 142
Self-citationEpigenetic Modification of CCAAT/Enhancer Binding Protein α Expression in Acute Myeloid Leukemia
Hackanson, B., Bennett, K. L., Brena, R. M., Jiang, J., Claus, R., Chen, S.-S., Blagitko-Dorfs, N., Maharry, K., Whitman, S. P., Schmittgen, T. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0483 · Cited by 140
“No significant differences were seen in the normal karyotype (median, 2%), t(8;21) (median, 3%), t(9;11) (median, 3%), and complex karyotype patient samples (median, 4%).”
BackgroundMethodResultInfluentialMarcucci, G., Mrózek, K., & Bloomfield, C. D. (2004) · Current Opinion in Hematology · doi:10.1097/01.moh.0000149608.29685.d1 · Cited by 131
Ptasinska, A., Assi, S. A., Martinez-Soria, N., Imperato, M. R., Piper, J., Cauchy, P., Pickin, A., James, S. R., Hoogenkamp, M., Williamson, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.024 · Cited by 135
“Many such mutations affect transcription factors that are crucial for the development of hematopoietic stem cells or for terminal myeloid differentiation, such as RUNX1 and C/EBP α , respectively (Gaidzik et al., 2011; Michaud et al., 2002; Pabst et al., 2001b; Snaddon et al., 2003).”
InfluentialSelf-citationGuibal, F. C., Alberich-Jorda, M., Hirai, H., Ebralidze, A., Levantini, E., Di Ruscio, A., Zhang, P., Santana-Lemos, B. A., Neuberg, D., Wagers, A. J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182071 · Cited by 126
Self-citationDown-regulation and antiproliferative role of C/EBPalpha in lung cancer.
Halmos, B., Huettner, C. S., Kocher, O. N., Ferenczi, K., Karp, D. D., & Tenen, D. G. (2002) · PubMed · Cited by 135
Self-citationAl-harbi, S., Aljurf, M. D., Mohty, M., Almohareb, F. I., & Ahmed, S. O. A. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000168 · Cited by 132
C/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment
Yeamans, C., Wang, D., Paz-Priel, I., Torbett, B. E., Tenen, D. G., & Friedman, A. D. (2007) · Blood · doi:10.1182/blood-2007-03-080291 · Cited by 118
Self-citationAML1-ETO reprograms hematopoietic cell fate by downregulatingsclexpression
Yeh, J.-R. J., Munson, K. M., Chao, Y. L., Peterson, Q. P., MacRae, C. A., & Peterson, R. T. (2007) · Development · doi:10.1242/dev.008904 · Cited by 125
Porse, B. T., Bryder, D., Theilgaard-Mönch, K., Hasemann, M. S., Anderson, K., Damgaard, I., Jacobsen, S. E. W., & Nerlov, C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050067 · Cited by 117
The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML
Eyholzer, M., Schmid, S., Wilkens, L., Mueller, B. U., & Pabst, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605751 · Cited by 115
“We used leukaemic Kasumi-1 cells lacking detectable amounts of endogenous CEBPA, however, containing an inducible CEBPA-ER fusion construct (Pabst et al, 2001a).”
BackgroundMethodInfluentialSelf-citationHeath, V., Suh, H. C., Holman, M., Renn, K., Gooya, J. M., Parkin, S., Klarmann, K. D., Ortiz, M., Johnson, P., & Keller, J. (2004) · Blood · doi:10.1182/blood-2003-11-3963 · Cited by 114
Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia
Pabst, T., & Mueller, B. U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2941 · Cited by 114
“mRNA expression through inhibition of autoregulation (35).”
Self-citationTranscription factor fusions in acute leukemia: variations on a theme
Scandura, J. M., Boccuni, P., Cammenga, J., & Nimer, S. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205315 · Cited by 132
“Acquired dominant negative mutations of C/EBPa have been reported, and may occur in up to 17% of M2 AML with a normal karyotype (Pabst et al., 2001b).”
BackgroundResultInfluentialHarnessing the immune system in acute myeloid leukaemia
Austin, R. J., Smyth, M. J., & Lane, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.020 · Cited by 120
“A study found that the oncoproteins, AML1-ETO and PML-RARα mediate down-regulation of CD48 through recruitment of histone deacetylase (HDAC) [194] although the clinical significance of this work is still to be determined.”
InfluentialThe emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia
Mikesch, J.-H., Steffen, B., Berdel, W. E., Serve, H. L., & Müller‐Tidow, C. (2007) · Leukemia · doi:10.1038/sj.leu.2404732 · Cited by 128
Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2
Snaddon, J., Smith, M. L., Neat, M., Cambal‐Parrales, M., Dixon‐McIver, A., Arch, R., Amess, J. A., Rohatiner, A. Z., Lister, T. A., & Fitzgibbon, J. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10185 · Cited by 110
“The RUNX1-CBFA2T1 fusion protein, which occurs in 10–15% of cases of AML, causes an eightfold down-regulation of CEBPA expression (Pabst et al., 2001b).”
BackgroundResultInfluentialTranscriptional dysregulation during myeloid transformation in AML
Pabst, T., & Mueller, B. U. (2007) · Oncogene · doi:10.1038/sj.onc.1210765 · Cited by 120
“Also, at least one CEBPA mutation in AML has been reported whose activation potential in transfection assays exceeded several fold that of the wild-type construct (Pabst et al., 2001b).”
BackgroundInfluentialSelf-citationCCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia
Truong, B.-T. H. (2003) · Blood · doi:10.1182/blood-2002-05-1374 · Cited by 103
C/EBPα in normal and malignant myelopoiesis
Friedman, A. D. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1764-6 · Cited by 101
“12 % of AMLs harbor t(8;21), leading to expression of RUNX1-ETO, which binds RUNX1 cis elements to represses Cebpa transcription [132].”
Backgroundc-Myc as a therapeutic target in cancer
Prochownik, E. V. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.2.289 · Cited by 100
Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model
Fischer, M., Schwieger, M., Horn, S., Niebuhr, B., Ford, A. M., Roscher, S., Bergholz, U., Greaves, M. F., Löhler, J., & Stocking, C. (2005) · Oncogene · doi:10.1038/sj.onc.1208931 · Cited by 111
Effect of transcription-factor concentrations on leukemic stem cells
Rosenbauer, F., Koschmieder, S., Steidl, U., & Tenen, D. G. (2005) · Blood · doi:10.1182/blood-2005-02-0717 · Cited by 98
Self-citationD'Alo', F., Johansen, L. M., Nelson, E. A., Radomska, H. S., Evans, E. K., Zhang, P., Nerlov, C., & Tenen, D. G. (2003) · Blood · doi:10.1182/blood-2003-02-0479 · Cited by 98
Self-citationC/EBPα: A tumour suppressor in multiple tissues?
Schuster, M. B., & Porse, B. T. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.02.003 · Cited by 99
C/EBPα and the pathophysiology of acute myeloid leukemia
Mueller, B. U., & Pabst, T. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000190110.08156.96 · Cited by 112
Self-citationGuo, H. W., Ma, O., Speck, N. A., & Friedman, A. D. (2012) · Blood · doi:10.1182/blood-2011-12-397091 · Cited by 107
Helbling, D. C., Mueller, B. U., Timchenko, N. A., Schardt, J., Eyer, M., Betts, D. R., Jotterand, M., Meyer‐Monard, S., Fey, M. F., & Pabst, T. (2005) · Blood · doi:10.1182/blood-2004-11-4392 · Cited by 104
The CCAAT Enhancer-binding Protein α (C/EBPα) Requires a SWI/SNF Complex for Proliferation Arrest
Müller, C., Calkhoven, C. F., Sha, X., & Leutz, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312709200 · Cited by 105
The RUNX1–PU.1 axis in the control of hematopoiesis
Imperato, M. R., Cauchy, P., Obier, N., & Bonifer, C. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1762-8 · Cited by 94
“This exchange does not occur in t[8, 21] AML since RUNX1–ETO represses CEBPA, differentiation is thus blocked [122, 129].”
BackgroundDrug resistance in mutant FLT3-positive AML
Weisberg, E., Sattler, M., Ray, A., & Griffin, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.273 · Cited by 93
“Most AML patients have underlying genetic mutations that cause the production of precursor cells characterized by either a block in differentiation, aberrant and accelerated growth, or a combination of both (Olsson et al., 1996; Tanaka et al., 1997; Pabst et al., 2001).”
Promotion of Liver and Lung Tumorigenesis in DEN-Treated Cytoglobin-Deficient Mice
Thủy, L. T. T., Morita, T., Yoshida, K., Wakasa, K., Iizuka, M., Ogawa, T., Mori, M., Sekiya, Y., Momen, S., Motoyama, H., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.006 · Cited by 94
Chen, M., Zhu, N., Liu, X., Laurent, B., Tang, Z., Eng, R., Shi, Y., Armstrong, S. A., & Roeder, R. G. (2015) · Genes & Development · doi:10.1101/gad.267278.115 · Cited by 108
“Mechanisms that have been proposed for the function of AE in blocking differentiation include inhibition of the expression of C/EBPα (a bZIP transcription factor critical for granulocytic differentiation) (Pabst et al. 2001) and inhibition of the transcription activity of PU.”
Russell, L. J., Enshaei, A., Jones, L., Erhorn, A., Mašić, D., Bentley, H., Laczko, K. S., Fielding, A. K., Goldstone, A. H., Goulden, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.3242 · Cited by 96
Figueroa, M. E., Wouters, B. J., Skrabanek, L., Glass, J., Li, Y., Erpelinck-Verschueren, C. A. J., Langerak, A. W., Löwenberg, B., Fazzari, M., Greally, J. M., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172387 · Cited by 91
Sabatier, M., Birsen, R., Lauture, L., Mouche, S., Angelino, P., Dehairs, J., Goupille, L., Boussaid, I., Heiblig, M., Boët, E., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0411 · Cited by 110
Reilly, J. T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05236.x · Cited by 115
“Mutual exclusivity is also a feature of class II mutations since mutations of C/EBF and PU.1 are rare in the CBF leukaemias (Pabst et al, 2001a; Mueller et al, 2002).”
BackgroundCore Binding Factor Acute Myeloid Leukemia
Paschka, P. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.011 · Cited by 100
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
Mrózek, K., Marcucci, G., Paschka, P., & Bloomfield, C. D. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831369df · Cited by 89
Tonks, A., Pearn, L., Musson, M., Gilkes, A., Mills, K., Burnett, A. K., & Darley, R. L. (2007) · Leukemia · doi:10.1038/sj.leu.2404961 · Cited by 98
Helbling, D., Mueller, B. U., Timchenko, N. A., Hagemeijer, A., Jotterand, M., Meyer‐Monard, S., Lister, A. T., Rowley, J. D., Huegli, B., Fey, M. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404731101 · Cited by 100
Self-citationCore binding factor genes and human leukemia.
Hart, S., & Foroni, L. (2002) · PubMed · Cited by 103
Induction of C/EBPα activity alters gene expression and differentiation of human CD34+ cells
Cammenga, J., Mulloy, J. C., Berguido, F. J., MacGrogan, D., Viale, A., & Nimer, S. D. (2003) · Blood · doi:10.1182/blood-2002-05-1546 · Cited by 85
Metadata
- Authors
- Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Helmholtz Munich (DE)
- Scripps Research Institute (US)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Medicine
- Published
- 2001-04
- Volume
- 7
- Issue
- 4
- Pages
- 444-451
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1489323849
- Semantic Scholar
- 0dc02b7bfde7f6d2b964fdb5715593ac0bec54f2
- Cited by
- 463
- References
- 45
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 12 · 2022: 4 · 2021: 16 · 2020: 8 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 18 · 2012: 18
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- AML1-ETO, C/EBPα, CEBPA, acute myeloid leukemia, granulocytic differentiation, transcriptional repression, conditional gene expression, U937 cells, Kasumi-1 cells, therapeutic target
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, Animals, Base Sequence, Cell Differentiation, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, DNA-Binding Proteins, Humans, Promoter Regions, Genetic, Proto-Oncogene Proteins, RNA, Messenger, RNA, Neoplasm, Transcription Factors, Translocation, Genetic, Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Down-Regulation, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, Core Binding Factor Alpha 2 Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.